Business Context and Reporting Period
This Form 8-K was filed by Compass Therapeutics, Inc. on November 1, 2021. The report addresses preliminary financial results for the third quarter ended September 30, 2021, and announces significant corporate developments including a proposed public offering of common stock and an uplisting to the Nasdaq Capital Market.
Key Financial Metrics
The filing provides preliminary, unaudited data only. Complete financial information for the quarter is not yet available.
- Cash and Cash Equivalents: Estimated at $25.5 million as of September 30, 2021.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: No specific debt figures are provided; liquidity is represented solely by the estimated cash balance.
Material Changes and Developments
Two primary events were reported on November 1, 2021:
- Proposed Public Offering: The Company intends to file a preliminary prospectus supplement for a public offering of its Common Stock under an existing shelf registration statement (Form S-3).
- Uplisting: The Company announced plans to uplist its common stock from the OTCQB Stock Exchange to the Nasdaq Capital Market.
- Clinical Advancement: The Company reported the advancement of its bispecific antibody candidate, CTX-009, to Phase 2a development for patients with biliary tract cancers, noting the clearance of a key clinical hurdle.
Guidance, Outlook, and Risks
Management cautioned that the estimated cash balance is preliminary and actual results may differ materially upon finalization of the quarterly closing process. The filing contains forward-looking statements regarding the completion of the public offering and the therapeutic potential of product candidates.
Key risks identified include uncertainties related to market conditions, the successful completion of the public offering on anticipated terms, and the development plans for product candidates. The Company assumes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final audited cash balance and full financial results for the quarter ended September 30, 2021, once the Company completes its closing process.
- Confirm the terms, pricing, and completion status of the proposed public offering of Common Stock.
- Monitor the regulatory approval and execution of the uplisting to the Nasdaq Capital Market.
- Review the detailed clinical data and trial design for the Phase 2a study of CTX-009 in biliary tract cancers.